SAREPTA THERAPEUTICS, INC. Net Income (Loss) Attributable to Parent, Diluted
SAREPTA THERAPEUTICS, INC. (SRPT) reported Net Income (Loss) Attributable to Parent, Diluted of $6.80 million for the 3-month period ending 2024-06-30, per its 10-Q filed 2024-08-07.
Discontinued › Income Statement
us-gaap:NetIncomeLossAttributableToParentDiluted · last filed 2024-08-07
- SAREPTA THERAPEUTICS, INC. net income (loss) attributable to parent, diluted for the quarter ending 2024-06-30 was $6.80M.
- SAREPTA THERAPEUTICS, INC. net income (loss) attributable to parent, diluted for the quarter ending 2024-03-31 was $36.55M.
- SAREPTA THERAPEUTICS, INC. net income (loss) attributable to parent, diluted for the quarter ending 2023-06-30 was -$23.94M.
- SAREPTA THERAPEUTICS, INC. net income (loss) attributable to parent, diluted for the quarter ending 2023-03-31 was -$516.75M.
| Period end | Net Income (Loss) Attributable to Parent, Diluted 3 month | Net Income (Loss) Attributable to Parent, Diluted 6 month |
|---|---|---|
| 2024-06-30 | $6.80M 10-Q · filed 2024-08-07 | $43.35M 10-Q · filed 2024-08-07 |
| 2024-03-31 | $36.55M 10-Q · filed 2024-05-01 | |
| 2023-06-30 | -$23.94M 10-Q · filed 2024-08-07 | -$540.70M 10-Q · filed 2024-08-07 |
| 2023-03-31 | -$516.75M 10-Q · filed 2024-05-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |